Janssen filed patent infringement suits in New Jersey and Delaware over proposed copy of blockbuster drug Invega Sustenna | Lawsuits follow appeals court win for J&J in separate action with Teva and ...

J&J(JNJ) wins U.S. appeals court case protecting its Invega Sustenna patent from generic rivals Viatris (VTRS) & Teva (TEVA).

Johnson & Johnson convinced a U.S. appeals court on Tuesday to reject a bid from generic drugmakers Teva and Viatris to ...

The TTC says a streetcar was “thoroughly cleaned” after a rider reported a syringe tucked beneath one of the seats. The syringe was found on a 501 Queen streetcar travelling eastbound on ...

INVEGA HAFYERA ®, INVEGA TRINZA ® and INVEGA SUSTENNA ® are not for the treatment of people with dementia-related psychosis.

Invega Sustenna is a prescription drug used for schizophrenia and schizoaffective disorder. Learn about its side effects, uses, dosage, and more.

Results showed that once-monthly Invega Sustenna is effective at reducing symptom severity. People taking Sustenna showed an improvement in PANSS scores compared to those taking the placebo.

Teva already presented in June 2024 data informing clinical strategies for switching patients to UZEDY from a once-monthly intramuscular injection of Invega Sustenna® (paliperidone palmitate)**.

However, the treatment was well tolerated, with no unexpected treatment-emergent AEs compared to Invega Sustenna. 2 According to the World Health Organization (WHO), schizophrenia affects ...

U.S. District Judge Claire Cecchi determined in Teva's case in 2021 that it failed to prove that J&J's patent, covering a dosing regimen for Invega Sustenna, was invalid.

J&J sold more than $4.1 billion worth of Invega Sustenna and related drugs worldwide last year, with nearly $2.9 billion in U.S. sales, according to a company report. It sued Teva and Mylan, which ...